Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 2/20 | 0.50 |
| ▸ | CASP5 | P51878 | 2/20 | 0.50 |
| ▸ | CASP4 | P49662 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.41 |
| ▸ | AKT1 | P31749 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | GALR2 | O43603 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3717904 | 0.99 | CASP1 (0.49) | CASP1CASP5CASP4HSD17B10LMNA | |
| SCHEMBL16013548 | 0.89 | PIK3CA (0.48) | HSD17B10LMNATSHRMAPK1KDM4E | |
| SCHEMBL16012936 | 0.85 | HRH3 (0.46) | CASP1CASP5CASP4RPS6KB1AKT1 | |
| SCHEMBL16012907 | 0.84 | CASP1 (0.43) | CASP1CASP5CASP4RPS6KB1AKT1 | |
| SCHEMBL10163853 | 0.83 | KMT2A (0.49) | HSD17B10LMNAUSP2TSHRHTT | |
| SCHEMBL16005109 | 0.82 | LTA4H (0.49) | CASP1LTA4HNPBWR1 | |
| SCHEMBL20254165 | 0.78 | AKT2 (0.48) | CASP1CASP5CASP4LMNALTA4H | |
| SCHEMBL3727146 | 0.78 | PRKD1 (0.56) | CASP1CASP5CASP4HSD17B10LMNA | |
| Hydrochloric Acid SCHEMBL20210908 | 0.77 | AKT2 (0.47) | CASP1CASP5CASP4LMNALTA4H | |
| SCHEMBL28824391 | 0.77 | LMNA (0.46) | CASP1CASP5CASP4HSD17B10LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8614201-B2 | Heterocyclic amides as modulators of TRPA1 | JANSSEN PHARMACEUTICA NV (BE) | 2013-12-24 | — | — | US | claimed |
| WO-2010141805-A1 | HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-09 | — | — | WO | claimed |
| US-9409864-B2 | Sulfonamide TRPA1 receptor antagonists | ARIO PHARMA LIMITED (GB) | 2016-08-09 | — | — | US | disclosed |
| US-20160024009-A1 | Novel Sulfonamide TRPA1 Receptor Antagonists | ARIO PHARMA LIMITED (GB) | 2016-01-28 | — | — | US | disclosed |
| EP-2964615-A1 | NOVEL SULFONAMIDE TRPA1 RECEPTOR ANTAGONISTS | Ario Pharma Limited (GB) | 2016-01-13 | — | — | EP | disclosed |
| WO-2014135617-A1 | NOVEL SULFONAMIDE TRPA1 RECEPTOR ANTAGONISTS | PHARMESTE S.R.L. IN LIQUIDATION (IT) | 2014-09-12 | — | — | WO | disclosed |
| EP-2774919-A1 | Novel sulfonamide TRPA1 receptor antagonists | PHARMESTE S.R.L. IN LIQUIDAZIONE (IT) | 2014-09-10 | — | — | EP | disclosed |
| US-8614201-B2 | Heterocyclic amides as modulators of TRPA1 | JANSSEN PHARMACEUTICA NV (BE) | 2013-12-24 | — | — | US | disclosed |
| US-20120083474-A1 | HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 | JANSSEN PHARMACEUTICA NV (BE) | 2012-04-05 | — | — | US | disclosed |
| US-20120083474-A1 | HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 | JANSSEN PHARMACEUTICA NV (BE) | 2012-04-05 | — | — | US | disclosed |
| WO-2010141805-A1 | HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-09 | — | — | WO | disclosed |
| WO-2010141805-A1 | HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024009-A1 | Novel Sulfonamide TRPA1 Receptor Antagonists | TRPA1, TRPV1, TRPV2 | CASP1 744/4885CASP5 1708/4885CASP4 2248/4885 |
| US-20120083474-A1 | HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 | TRPA1, TRPV1, TRPV2 | CASP1 359/4885CASP5 1420/4885CASP4 1249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.